2.28
+0.13(+6.05%)
Currency In USD
| Previous Close | 2.15 |
| Open | 2.14 |
| Day High | 2.37 |
| Day Low | 2.11 |
| 52-Week High | 10.14 |
| 52-Week Low | 1.78 |
| Volume | 286,667 |
| Average Volume | 394,475 |
| Market Cap | 47.63M |
| PE | -0.32 |
| EPS | -7.22 |
| Moving Average 50 Days | 2.61 |
| Moving Average 200 Days | 4.87 |
| Change | 0.13 |
If you invested $1000 in Adverum Biotechnologies, Inc. (ADVM) 10 years ago, it would be worth $14.19 as of July 01, 2025 at a share price of $2.28. Whereas If you bought $1000 worth of Adverum Biotechnologies, Inc. (ADVM) shares 5 years ago, it would be worth $10.82 as of July 01, 2025 at a share price of $2.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
GlobeNewswire Inc.
May 14, 2025 8:05 PM GMT
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expres
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
May 02, 2025 8:01 PM GMT
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
GlobeNewswire Inc.
Mar 31, 2025 8:01 PM GMT
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that